Overview

Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare in very early polyarticular juvenile idiopathic arthritis (JIA) the efficacy, safety, and cost-benefit-ratio of three treatment strategies: biologic combination, combination of conventional disease-modifying drugs (DMARDs), and methotrexate alone.
Phase:
Phase 3
Details
Lead Sponsor:
Helsinki University Central Hospital
Collaborators:
Foundation for Paediatric Research, Finland
Paijat-Hame Hospital District
Päivikki and Sakari Sohlberg Foundation, Finland
Rheumatism Foundation Hospital
Scandinavian Rheumatology Research Foundation
Treatments:
Antirheumatic Agents
Infliximab
Methotrexate
Naltrexone
Sulfasalazine